Skip to content

13F-HR filed by Lynx1 Capital Management LP

Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 21:13:54 UTC, with 31 holding rows worth $646,092,908.

Accession
0001910456-26-000007
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 31 entries on the cover page, a total value of $646,092,908 stated on the cover page (in dollars after the unit check, H1), rows summing to $646,092,908 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.

Other managers

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
GH RESEARCH PLC ORDINARY SHARESG3855L106Stock13,263,288$311,422,002dollars as filed
CULLINAN THERAPEUTICS INC230031106COM8,963,500$137,589,725dollars as filed
STOKE THERAPEUTICS INC86150R107COM3,896,169$101,300,394dollars as filed
C4 THERAPEUTICS INC12529R107COM STK7,530,915$25,077,947dollars as filed
PRECISION BIOSCIENCES INC74019P207COM NEW2,758,215$17,266,426dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM472,606$15,714,150dollars as filed
KORRO BIO INC500946108COMMON STOCK1,544,980$15,310,752dollars as filed
NEUPHORIA THERAPEUTICS INC64136E102COM875,328$3,116,168dollars as filed
PASSAGE BIO INC702712209COM NEW673,759$3,031,914dollars as filed
PROQR THERAPEUTICS NVN71542109SHS EURO1,562,093$2,593,074dollars as filed
Tscan Therapeutics Inc89854M101COM8,019,148$2,522,022dollars as filed
KAZIA THERAPEUTICS LTD48669G303SPONSORED ADS225,800$2,166,551dollars as filed
PLIANT THERAPEUTICS INC729139105COM1,798,070$1,941,916dollars as filed
ENTRADA THERAPEUTICS INC COM29384C108Stock278,606$1,769,148dollars as filed
SURROZEN INC86889P208COMMON STOCK20,000$643,600dollars as filed
IMMATICS N.VN44445109SHS71,263$625,689dollars as filed
WEREWOLF THERAPEUTICS INC95075A107CMN657,786$606,676dollars as filed
Yarrow Bioscience, Inc.92941V407Common Stock, $0.0001 par value22,000$495,440dollars as filed
XENCOR INC98401F105COMMON STOCK18,194$453,940dollars as filed
IMMUNOCORE HLDGS PLC ADS45258D105ADR14,300$433,147dollars as filed
DYNE THERAPEUTICS INC COM26818M108Stock25,000$402,750dollars as filed
TRAWS PHARMA INC68232V884COM NEW559,470$332,213dollars as filed
DENALI THERAPEUTICS INC COM24823R105Stock11,658$240,971dollars as filed
ABSCI CORPORATION00091E109COM21,245$228,809dollars as filed
FOGHORN THERAPEUTICS INC344174107COMMON STOCK61,588$219,869dollars as filed
AVALO THERAPEUTICS INC05338F306COMMON STOCK10,100$154,833dollars as filed
PRIME MEDICINE INC74168J101COM45,000$137,475dollars as filed
BOLT BIOTHERAPEUTICS INC097702203COM NEW30,800$113,344dollars as filed
EUPRAXIA PHARMACEUTICALS INC29842P105COM 298736 AL 3 EURONET WORLDWIDE INC NOTE 0.750% 3/110,000$91,000dollars as filed
NUVATION BIO INC COM CL A67080N101Stock16,029$89,762dollars as filed
INHIBIKASE THERAPEUTICS INC45719W205COMMON STOCK20,000$1,201dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001910456-26-000007this filing2026-11-16